Seattle, Wash. (PRWEB) April 18, 2013
For Immediate Release—April 18, 2013
Cancer Treatment Centers of America Appoints Chief Medical Officer of the Cancer Research and Biostatistics (CRAB) Clinical Trials Consortium (Seattle) to Director of Clinical Research
SEATTLE—Cancer Treatment Centers of America® (CTCA) announced today that Glen J. Weiss, M.D., has been named the Director of Clinical Research. Dr. Weiss is also currently the Chief Medical Officer of Seattle’s Cancer Research and Biostatistics (CRAB)® Clinical Trials Consortium, a position he was elected to in 2011. CTCA’s patient base from Washington and Oregon has grown year over year since 2009, with 70 patients from Washington and Oregon having sought care at CTCA in 2012.
At CTCA, Dr. Weiss will be leading corporate-wide strategy and implementation of Phase I and II clinical trial initiatives based out of its Western Regional Medical Center (Western) in Goodyear, Ariz.
Prior to joining CTCA®, Dr. Weiss served as the Director of Thoracic Oncology and Associate Clinical Investigator with the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare. He is a Clinical Associate Professor, Translational Physician Scientist, and Co-Head of the Lung Cancer Unit of the Cancer and Cell Biology Division at the Translational Genomics Research Institute (TGen) in Phoenix.
“At CTCA, we have always prided ourselves on hiring the best and brightest of the medical community in an effort to provide the most technologically-advanced and innovative treatment options to our patients. We are excited to not only add Dr. Weiss to this group of distinguished physicians, but also to partner with him on the next new and exciting chapter at CTCA—clinical research,” said Western President and CEO Dr. Edgar Staren. “Each and every day, it is our mission to deliver the Mother Standard® of care to our patients and empower them with the right information and treatment options to help them win their fight against cancer. The innovative research work that Dr. Weiss will be leading, helps us fulfill that promise to our patients and provide advances that can benefit those fighting this disease around the country and even around the world.”
As part of the Western medical team, Dr. Weiss joins the staff of 161 oncology-specialized physicians, who were able to assist nearly 700 patients last year alone. In addition to leading the strategy and implementation of Phase I and II clinical trials across the enterprise, Dr. Weiss will develop and recruit members for the clinical research team and facilitate the implementation of innovative diagnostic and treatment modalities. He will also serve as an interface between laboratory investigators and clinical researchers towards accelerating new developments in cancer therapy and diagnostics. Additionally, in his role as a medical oncologist he will evaluate patients with cancer, particularly those with lung, skin, and rare uncommon malignancies, for treatment that may include offering participation in early phase clinical studies.
Dr. Weiss has published more than 150 peer-reviewed articles and abstracts in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Clinical Cancer Research and Journal of Thoracic Oncology. He has been invited to present at venues around the world, including Seoul, South Korea; Orleans, France; Vienna, Austria; and Budapest, Hungary.
Board certified in internal medicine and medical oncology, Dr. Weiss has already completed numerous clinical trials with investigational agents, a few of which have already gone on to receive FDA approval for certain cancers. He has also received research funding from the American Cancer Society and the International Association for the Study of Lung Cancer, to name a few.
“I deliver novel, targeted and investigational therapies for advanced cancer patients,” says Dr. Weiss. “Using new tools in genomics and proteomics, I help design personalized therapies for advanced cancer patients based on the unique biology of their tumor. I hope that the innovative treatments developed in the clinical trials program at CTCA will become standard of care in oncology, and will thus benefit a larger patient population in the future.”
Dr. Weiss earned a medical degree from Sackler School of Medicine in Tel Aviv, Israel. He then completed an internal medicine residency at SUNY-Downstate in Brooklyn, New York. He went on to finish a hematology/medical oncology fellowship at the University of Colorado Health Sciences Center in Aurora, serving as the Chief Fellow in his final year.
We’d love to set up an interview or Google+ hangout with Dr. Weiss—please let us know if we can facilitate an introduction.
About Cancer Treatment Centers of America
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to http://www.cancercenter.com.
Sarah Stephan or Emily Goetz